Loading...
XNASCAPR
Market cap572mUSD
Jan 14, Last price  
12.59USD
1D
-1.02%
1Q
-38.62%
Jan 2017
-52.67%
Name

Capricor Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CAPR chart
P/E
—
P/S
22.74
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
55.54%
Rev. gr., 5y
72.02%
Revenues
25m
+887.79%
000101,4000001,354,500195,500503,2334,786,7003,776,0413,190,1061,367,1861,671,3561,005,028310,250244,8982,548,91725,178,066
Net income
-22m
-18,077-18,861-61,354-10,302,795-13,131,596-7,872,297-6,031,491-4,884,786-1,893,037-8,891,924-6,216,592-12,857,339-18,806,7762,431,423-15,191,095-7,377,790-13,480,195-19,409,1080-22,287,542
CFO
-26m
L
-15,479-17,790-55,597-5,372,617-10,640,044-5,795,494-4,318,264-4,649,292-2,186,681-6,144,001958,562-10,817,286-15,801,620-14,230,879-13,862,441-6,821,501-10,054,810-16,809,3244,916,637-25,596,545
Earnings
Feb 26, 2025

Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
URL
https://capricor.com/
IPO date
Jun 04, 2002
Employees
74
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
25,178
887.79%
2,549
940.81%
Cost of revenue
49,882
32,944
Unusual Expense (Income)
NOPBT
(24,704)
(30,395)
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
(24,704)
(30,395)
Net income
(22,288)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
25,515
4,804
BB yield
-19.49%
-5.07%
Debt
Debt current
749
682
Long-term debt
3,723
4,438
Deferred revenue
9,468
Other long-term liabilities
3,376
3,376
Net debt
(35,016)
(36,301)
Cash flow
Cash from operating activities
(25,597)
4,917
CAPEX
(2,048)
(3,360)
Cash from investing activities
5,108
(35,073)
Cash from financing activities
25,580
4,874
FCF
(25,377)
(32,715)
Balance
Cash
39,488
41,421
Long term investments
Excess cash
38,229
41,294
Stockholders' equity
(159,100)
(136,949)
Invested Capital
187,314
164,140
ROIC
ROCE
EV
Common stock shares outstanding
26,778
24,553
Price
4.89
26.68%
3.86
31.74%
Market cap
130,946
38.17%
94,773
40.09%
EV
95,930
58,472
EBITDA
(23,635)
(29,862)
EV/EBITDA
Interest
Interest/NOPBT